Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
January 23, 2025 18:41 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL ROCKVILLE,…